Holen Sie sich die Stockscreener-App
60.36
4.79%
2.76
Handel nachbörslich:
60.36
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez - The Globe and Mail
MNPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monopar names Susan Rodriguez as chief commercial officer - Investing.com India
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - Bitget
Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer - marketscreener.com
New Monopar (NASDAQ: MNPR) strategy chief to steer ALXN1840 NDA - Stock Titan
Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 - marketscreener.com
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research - MarketBeat
Is Monopar Therapeutics Inc. stock ready for breakoutWeekly Trading Summary & Accurate Intraday Trade Tips - mfd.ru
Can Monopar Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Retail Trends: Will Monopar Therapeutics Inc benefit from sector rotationPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Understanding the Setup: (MNPR) and Scalable Risk - Stock Traders Daily
RA Capital reports 9.99% Monopar Therapeutics stake in Schedule 13G/A (MNPR) - Stock Titan
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Monopar Therapeutics (NASDAQ:MNPR) Head to Head Comparison - Defense World
Why Monopar Therapeutics Inc. (1IY0) stock attracts wealthy investors2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - mfd.ru
MNPR PE Ratio & Valuation, Is MNPR Overvalued - Intellectia AI
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Should I add Monopar Therapeutics Inc. stock to my portfolio2025 Retail Activity & AI Based Trade Execution Alerts - mfd.ru
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Technical Reactions to MNPR Trends in Macro Strategies - Stock Traders Daily
Price Action: Is Monopar Therapeutics Inc impacted by rising rates2025 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
History Review: Is CO2 Energy Transition Corp a stock for growth or value investors2025 Geopolitical Influence & High Win Rate Trade Tips - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Nuvalent (NUVL) and Monopar Therapeutics Inc (MNPR) - The Globe and Mail
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):